Table Of Content

Breast Cancer Research and Treatment 59 289-290, 2000 2000 Kluwer Ac adele P (D1i) ] Shes Printe a j iint i oth te Nether ands Author index, Volume 59 Aittomiki K 101 Emerman J] 199 Kasumi F 177 Andrews HN_ 199 Kennedy KA 15 Arencibia JM 255 Fabi A 223 Kerr LR 199 Ashley S_ 171 Fernandez PM 15 Kirk J 10] Ashok S163 Ferné M ¢ Y Kirwan-Rhude AF 3] Ferraresi \ 992 Kurt RA 41 BacchiM 279 Friedlander M LO] Baldetorp B 69 Fukushima Y 2) Lee AS S| Barratt A 101 Lionetto R 133 Bastert G 271 Gatt C 101 Ljung B-M 113 Batra S 163 Gallo L133+ 4 Bengala C 133 Gannon BI 2 _2 3] Magklara A 263 177 Bernhard J 279 Garufi C 292?2 3 Makita M Bharaj B 153 Gatti C 211 Malmstr6m P 69 Biganzoli E 211 Gelman R) 49 Manning FCR 15 Black MH_ | Giait M_ 153 Mansel R 245 Blais DE 231 Gion M 21 il Marsella \ 223 Bonnetoi H 279 Gluck S + 7 } Matsumoto K 245 Boracchi P 211 Goel R= 55 Mayall B 113 N\ Bornstein BA 49 Goldhirsch A 2 9 Meiser B_ 101 Bove L 223 Gollan ¢ ,71 | Meo S 211 Bruynseels J 55 Goodson WH III [13 Meyberg GC aritt Butow P_ 101 Goss PE 55 Michelotti A 11 33 Grass | 2+ 63 Milella M 223 ‘arnino F 133 Gregory Miller FR 27 ‘astiglione M 279 Groot K Montanaro E 133 hadderton A 231] Moore DH II 113 ‘hang JC 171 Haan EI ‘hen X 81 Halmos G Nabholtz J-M 55 ‘hew K 113 Hamann 1 185 Nagy A 255 49 ‘onnolly JL. 49 Harris JR Nakamura T 245 onte 'P 135 Hatschek 1 69 NisticOC 223 ‘rump M 55 Herrmann R 27 9 Nixon AJ 49 Hetelekidis S 49 Nordenskj6ld B 69 D’Attino RM 223 Hiscox § 245 D’Ottavio AM 223 Hung G § | Ouatas T 27 79 Daniels IR 77 Hurny C Oza A 55 De Coster R 55 Husain SA 163 De Marco S 223 Paccagnella A 211 Del Mastro L133 Izzo | d1a9d2o Pace A 223 Dennert G 81 Parissenu AM 231 Parr C 245 Deo S 163 Jac bs LK Diamandis EP 1,115232,92762(3 Jiang WG Patierno SR 15 Diel IJ 271 Peiro G 49 Dittadi R 211 Kahan Z Peloso L 211 Perey L Dowsett M_ 171 Killstr6m A-C 279 290 = Author index, Volume 5S Powles TJ 171 Sinn H-P 185 Uchida Y 177 Smith HS 113 Urba WJ 41 Querci della Rovere G Solomayer E-F 271 Raina V_ 163 Stal O 69 Vaccaro A 223 Ray G 163 Steeg PS 27 Vassilikos EJK 153 Recht A 49 Sterns EE | 25 Venturini M_ 133 Reid C 55 Stetler-Stevenson M 7 Villeneuve DJ 231 Strange KS 199 Vinante O 211 Rosabian A 211 Rosso R= 133 Rydén S 69 Tabbara SO 15 Wadden N 55 fadaT i777 Waldman FM 113 Sabbiont MEE 279 Takahashi K 177 Weinberg J 199 Saito M 177 Terzoli E 29223 Wultkuhle J 27 SalterJ 171 Thiirlimann B 279 Schally AV 255 Pibaldi C 133 Yamakawa M_ 1/41 Schnitt SJ 49 Tropea F 223 Yoshimoto M_— 177 Schoof DD 41 Psangaris TN 15 Yu H 153 Schwartz AM_ 15 rsuge T 141 Shukla NK 163 Tsukamoto M_ 141 Zee B 125 Siegrist HP 279 Tucker K 101 Zhang D 81 Tye LM 55 Silver B 49 Zhou Q 27 Breast Cancer Research and Treatment 59: 291-293, 2000. © 2000 Kluwer Academic Publishers. Printed in the Netherlands Subject index, Volume 59 adjuvant therapy cellular immunity 5 vs. 2 years tamoxifen beneficial for ER+/PgR+ association of NK cell count, 6,-microglobulin, but not ER+/PgR-— breast cancer 69-76 and sIL-2r with good prognostic factors erbB-2 as a predictor of response 171-175 279-287 anchorage-independent growth chemoresponse prediction stimulated preferentially by cyclin DI transfection see predictive factors into MCFIOA cells 27-39 chemotherapy androgen receptor active cytotoxic LH-RH conjugate in MDA-MB- and differential steroid regulation of PSA, human 231 xenografts 255-262 glandular kallikrein 263-270 activity and cardiotoxicity of single agent epirubi- shorter CAG repeats in more aggressive breast cin in first line 133-139 cancer 153-161 weekly vinorelbine with G-CSF support 223-229 antioxidant status conservative surgery and free radical production, lipid peroxidation, in lobular carcinoma outcomes similar to ductal 49- breast cancer 163-170 54 and the prognostic implication of TPA, cytokeratin cyclin D1 fragments 211-221 transfection into MCFIOA cells stimulates only drug-induced — resistance caused by induce anchorage-independent growth 27-39 GRP78 15-26 cytokeratin fragments P-glycoprotein inhibitor restores Taxol sensitivity and tissue polypeptide antigen (TPA) in prognosis of apoptosis in drug resistant MCF-7 231-244 211-221 aromatase inhibitors cytokines liarozole phase II trial — retinoid-type toxicities in breast tumors, and types of infiltrating and 55-68 adjacent dendritic cells 141-152 axillary anatomy cytotoxic conjugates variations — a case of “Axillary Arch of Langer" activity of 2-pyrrolinodoxorubicin linked to LH-RH 77-80 on MDA-MB-231 xenografts 255-262 bone metastasis dendritic cells better prognosis than visceral site of first meta- distinct types in and around tumor nests, and tumor stasis 271-278 cytokine expression 141-152 BRCA] drug resistance age, tumor properties, and survival in hereditary association with GRP78 overexpression and resis- breast cancer with and without BRCAI tance to apoptosis 15-26 mutation 185-192 P-glycoprotein inhibitor restores Taxol sensitivity breast cancer associated gene | (bceg-1) of apoptosis in resistant MCF-7 231-244 tissue specificity of new gene found by subtractive hybridization in breast tumors 41-48 bromodeoxyuridine (BrdU) endocrine therapy vs. Ki-67 proliferation index in prognosis 113-123 5 vs. 2 years adjuvant tamoxifen beneficial for ER+/Pgr+ but not ER+/PgR-— breast cancer c-met receptor 69-76 HGP/SF variant NK4 inhibits HGF/SF-induced liarozole (aromatase inhibitor and retinomimetic) phosphorylation, invasion 245-254 phase II trial 55-68 catalase epirubicin and antioxidant status, free radical production, in activity and cardiotoxicity as single agent in first breast cancer 163-170 line 133-139 292 = Subject index, Vol. 59 erbB-2 immune memory predicting response and survival with neoadjuvant induced by HSVtk under GRP78 promoter 81-90 vs. adjuvant chemoendocrine therapy 171-175 Immune response cytokines in tumors, and types of infiltrating and familial breast cancer adjacent dendritic cells 141-152 age, tumor properties, and survival in hereditary immune status breast cancer with and without BRCA1 association of NK cell count, 6,-microglobulin, mutation 185-192 and sIL-2r with good prognostic factors 279-287 characteristics affecting mammography compliance in high risk women 101-111 free radical production kallikreins and antioxidant status, lipid peroxidation, in breast and activation of PSA 1-14 cancer 163-170 PSA and human glandular kallikrein — differential steroid regulation in breast cancer cells G-CSF 263-270 with weekly dose-intense vinorelbine 223-229 gene therapy BrdU proliferation index in prognosis 113-123 eradication of mouse mammary cancer using GRP78 promoter with HSVtk 81-90 genes in breast cancer liarozole phase II trial — aromatase inhibitor and retino- new and known genes identified by subtractive mimetic activities and toxicities 55-68 hybridization of fresh specimens 41-48 lipid peroxidation o lucose-regulated stress protein GRP78 and antioxidant status, free radical production, in directing HSVtk suicide gene therapy 81-90 breast cancer 163-170 overexpression in malignant but not benign breast liver metastasis lesions 15-26 benefit of surgical treatment 177-184 glutathione peroxidase lobular carcinoma and antioxidant status, free radical production, in same Outcomes as ductal with conservative surgery breast cancer 163-170 and radiation 49-54 luteinizing hormone-releasing hormone receptors heat shock proteins target for active cytotoxic LH-RH conjugate in and SC115 tumor growth in mice effects of MDA-MB-231 xenografts 255-262 social housing condition 199-209 hepatectomy in treatment of liver metastases 177-184 malondialdehyde hepatocyte growth factor / scatter factor (HGF/SF) and antioxidant status, free radical production, in variant NK4 inhibits HGF/SF-induced invasion breast cancer 163-170 245-254 mammographic density HER-2/neu decrease after menopause prevented by HRT 125- see erbB-2 132 hereditary breast cancer mammography see familial breast cancer characteristics affecting compliance in high risk high risk women women I0I-I11 characteristics affecting mammography compliance MCFI10A human breast cells 101-111 cyclin DI transfection stimulates only anchorage- hormone replacement therapy (HRT) independent growth 27-39 prevents post-menopausal decrease in mammo- metastasis graphic density 125-132 bone vs. visceral site of first metastasis, and HSVtk suicide gene therapy prognosis 271-278 eradication of mouse mammary cancer using HGF/SF variant NK4 inhibits HGF/SF-induced GRP78 promoter 81-90 invasion 245-254 Subject index, Vol. 59 neoadjuvant therapy radiation therapy erbB-2 as a predictor of response 171-175 lobular carcinoma outcomes similar to ductal 49-54 P-glycoprotein reactive oxygen metabolites inhibition restores paclitaxel sensitivity in resistant and antioxidant status, free radical production, in MCF-7 cells 231-244 breast cancer 163-170 paclitaxel induction of apoptosis restored by P-glycoprotein screening inhibitor in resistant MCF-7 cells 231-244 characteristics affecting attendance in high risk predictive factors women 101-111 erbB-2 in predicting response to neoadjuvant serum markers chemoendocrine therapy 171-175 prostate-specific antigen (PSA) in breast disease premalignant disease progression review 1-14 cyclin D1 transfection into MCFIOA cells Shionogi mouse mammary carcinoma (SC115) stimulates only anchorage-independent growth stress response proteins and tumor growth in mice 27-39 with different social housing conditions 199- progesterone receptor 209 5 vs. 2 years adjuvant tamoxifen beneficial for stress response proteins ER+/Pgr+ but not ER+/PgR- breast cancer 69- and SC115 tumor growth in mice — effects of 76 social housing condition 199-209 prognostic factors GRP78 overexpression in malignant but not benign association of NK cell count, §5-microglobulin, breast lesions 15-26 sIL-2r with good prognostic factors 279-287 subtractive hybridization bone vs. visceral site of first metastasis 271-278 genes overexpressed in breast cancer specimens BrdU vs. Ki-67 proliferation measures 113-123 41-48 erbB-2 in DFS with neoadjuvant vs. adjuvant superoxide dismutase chemoendocrine therapy 171 175 and antioxidant status, free radical production, in prostate-specific antigen (PSA) in breast disease — breast cancer 163-170 review 1-14 surgery shorter CAG repeats in androgen receptor gene and axillary variations — a case of "Axillary Arch of more aggressive breast cancer 153-161 Langer” 77-80 tissue polypeptide antigen (TPA) and cytokeratin benefit of hepatectomy for liver metastases 177 fragments 211-22 184 proliferation rate prognostic value of BrdU vs. Ki-67 113-123 tamoxifen prostate-specific antigen (PSA) 5 vs. 2 years beneficial for ER+/Pgr+ but not and human glandular kallikrein — differential ER+/PgR- breast cancer 69-76 steroid regulation in breast cancer cells 263- tissue polypeptide antigen (TPA) 270 and cytokeratin fragments in prognosis 211-22] review — diagnostic and prognostic use in breast disease 1-14 vinorelbine psychosocial stressors weekly schedule with G-CSF support 223-229 stress response proteins and SC115 tumor growth visceral metastasis in mice with different social housing conditions poorer prognosis than bone site of first metastasis 271-278 199-209